• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.

作者信息

Yau Kevin, Cherney David Z I, van Raalte Daniël H, Wever Britt E

机构信息

Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

出版信息

Kidney Int. 2024 Jun;105(6):1168-1172. doi: 10.1016/j.kint.2024.03.019.

DOI:10.1016/j.kint.2024.03.019
PMID:38777402
Abstract
摘要

相似文献

1
Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.钠-葡萄糖协同转运蛋白2抑制剂的肾脏保护机制：血流动力学效应的证据
Kidney Int. 2024 Jun;105(6):1168-1172. doi: 10.1016/j.kint.2024.03.019.
2
Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes.解析 SGLT2 抑制对肾脏血流动力学的影响：将 2 型糖尿病大鼠研究结果转化至人体。
Kidney Int. 2024 Sep;106(3):354-356. doi: 10.1016/j.kint.2024.06.018.
3
SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂作为代谢传感器，可恢复肾脏中健康的营养缺乏和过剩信号传导。
Kidney Int. 2024 Jun;105(6):1172-1176. doi: 10.1016/j.kint.2024.01.044.
4
Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.钠-葡萄糖共转运蛋白 2 抑制剂对糖尿病肾病的肾脏保护作用及其机制。
J Diabetes Complications. 2018 Jul;32(7):720-725. doi: 10.1016/j.jdiacomp.2018.04.011. Epub 2018 May 5.
5
Sweet success? SGLT2 inhibitors and diabetes.甜蜜的成功？钠-葡萄糖协同转运蛋白2抑制剂与糖尿病
Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1034-F1035. doi: 10.1152/ajprenal.00557.2017. Epub 2017 Dec 27.
6
Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的肾保护潜力：来自临床和真实世界数据的综合证据。
Eur J Pharmacol. 2021 Sep 15;907:174320. doi: 10.1016/j.ejphar.2021.174320. Epub 2021 Jul 8.
7
Are SGLT2 Inhibitors Ready for Prime Time for CKD?钠-葡萄糖协同转运蛋白2抑制剂对慢性肾脏病而言已准备好进入黄金时期了吗？
Clin J Am Soc Nephrol. 2018 Feb 7;13(2):318-320. doi: 10.2215/CJN.07680717. Epub 2017 Sep 11.
8
SGLT2 inhibitors: not every drug has the same effect.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：并非每种药物都有相同的效果。
Am J Physiol Renal Physiol. 2024 Jun 1;326(6):F1039-F1040. doi: 10.1152/ajprenal.00126.2024. Epub 2024 May 2.
9
Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.钠-葡萄糖协同转运蛋白2抑制剂预示着糖尿病肾病防治行动的号角。
Clin J Am Soc Nephrol. 2020 Feb 7;15(2):285-288. doi: 10.2215/CJN.07730719. Epub 2019 Nov 18.
10
[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].[在2型糖尿病合并糖尿病肾病伴蛋白尿的患者中，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂卡格列净对肾脏和心血管结局有何影响？]
Rev Med Interne. 2020 Jan;41(1):67-68. doi: 10.1016/j.revmed.2019.11.004. Epub 2019 Dec 4.

引用本文的文献

1
Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study.肾素-血管紧张素系统（RAS）抑制剂和钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂单用或联用对糖尿病合并高血压患者终末期肾病和/或全因死亡的影响：一项全国性队列研究
Cardiovasc Diabetol. 2025 Jul 14;24(1):288. doi: 10.1186/s12933-025-02846-x.
2
Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial.恩格列净与利格列汀单药及联合治疗和格列齐特相比，对超重2型糖尿病患者空腹及餐后肾脏血流动力学的影响（RACELINES）：一项随机、双盲试验
Diabetes Obes Metab. 2025 Jul;27(7):3943-3956. doi: 10.1111/dom.16431. Epub 2025 May 6.
3
Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence.住院患者早期使用钠-葡萄糖协同转运蛋白2抑制剂：基于当前证据的实用指南
ESC Heart Fail. 2025 Aug;12(4):2631-2642. doi: 10.1002/ehf2.15293. Epub 2025 Apr 17.
4
The systemic and kidney hemodynamic response to empagliflozin, losartan and their combination varies between individuals.恩格列净、氯沙坦及其联合用药对全身和肾脏血流动力学的反应存在个体差异。
J Nephrol. 2025 Apr 12. doi: 10.1007/s40620-025-02289-3.
5
Repurposing mitochondria-targeted therapeutics for kidney diseases.将线粒体靶向治疗药物用于肾脏疾病的新用途。
Kidney Int. 2025 Apr;107(4):617-627. doi: 10.1016/j.kint.2024.12.020. Epub 2025 Jan 22.
6
Focal Segmental Glomerulosclerosis With Superimposed Infection-Related Glomerulonephritis in a Diabetic Patient: A Case of Rapid Renal Decline.一名糖尿病患者合并局灶节段性肾小球硬化及感染相关性肾小球肾炎：一例快速肾脏衰退病例
Clin Case Rep. 2024 Nov 20;12(11):e9593. doi: 10.1002/ccr3.9593. eCollection 2024 Nov.
7
SGLT-2 inhibitors for the prevention of recurrent nephrolithiasis.用于预防复发性肾结石的钠-葡萄糖协同转运蛋白2抑制剂
BMJ. 2024 Nov 7;387:q2447. doi: 10.1136/bmj.q2447.